Form 4: Sarepta Therapeutics EVP Ryan Brown Reports Stock Transactions

EVP and General Counsel of Sarepta Therapeutics, Ryan Brown, reports acquisition and disposal of company stock and derivative securities, including transactions related to performance stock units and a 10b5-1 trading plan.

Summary

• Ryan Brown, EVP and General Counsel of Sarepta Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On June 21, 2024, Brown acquired 6,250 shares of common stock through the vesting of performance stock units (PSUs).
• Also on June 21, 2024, 5,500 shares were earned under a PSU award granted on March 7, 2022, which will vest on March 7, 2025.
• On June 24, 2024, 2,352 shares were sold by the company to cover tax obligations related to the vesting of PSUs at a price of $164.64.
• From June 25, 2024, Brown sold a total of 38,957 shares of common stock under a Rule 10b5-1 trading plan at prices ranging from $158.07 to $164.52.
• On June 25, 2024, Brown exercised a stock option for 23,500 shares at a price of $62.77.
• Following these transactions, Brown directly owns 17,129 shares of common stock and 5,500 performance stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of normal executive compensation and a pre-arranged trading plan. The vesting of PSUs is a positive sign, but the stock sales could be perceived negatively by some investors.

Positives

• The vesting of performance stock units indicates the company achieved certain milestones as determined by the Compensation Committee.
• The exercise of stock options demonstrates management's belief in the company's future prospects.

Negatives

• The sale of a significant number of shares by an executive could be perceived negatively by some investors, although it was conducted under a pre-arranged trading plan.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create short-term price volatility.
• Future performance stock unit vesting is contingent on the company achieving prescribed milestones.

Future Outlook

Future vesting of performance stock units is contingent upon continued service and the company's achievement of prescribed milestones.

Industry Context

Executive stock transactions are common in publicly traded companies and are often scrutinized by investors for insights into management's confidence in the company's prospects. Rule 10b5-1 plans are frequently used to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation practices, including the use of performance stock units, are common across the biotechnology industry.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize stock options and PSUs as part of their executive compensation packages.
• The vesting of PSUs based on the achievement of specific milestones is a standard practice to align executive incentives with company performance.

Stakeholder Impact

• Shareholders may be interested in the executive's transactions as an indicator of management's confidence.
• Employees may be impacted by the company's performance, which affects the vesting of performance-based compensation.

Next Steps

• The earned PSUs granted on March 7, 2022, will vest on March 7, 2025, subject to continued service.

Key Dates